Immunotech Biopharm Ltd (06978.HK)

Immunotech Biopharm Ltd. is an investment holding company, which through its subsidiaries engages in research and development, manufacturing and commercialization of immune cell products for treatments of cancers in the PRC. The company is headquartered in Beijing, Beijing and currently employs 173 full-time employees. The company went IPO on 2020-07-10. The firm's non-genetically modified cell product pipeline includes Expanded Activated Lymphocytes (EAL) and 6B11-OCIK Injection. The firm's chimeric antigen receptor T (CAR-T) cell product pipeline includes CAR-T-19 Injection, Denocabtagene Ciloleucel Injection and aT19 Injection. The firm's T cell receptor engineered T cell therapy (TCR-T) cell product pipeline includes YT003, YT008 and YT007. The firm mainly conducts its businesses in the domestic market.